Category Archives: Anti-Aging Medicine

Peter Attia, M.D., is a longevity expert and creator of

BLOOD-PRESSURE MANAGEMENT isnt a sexy topic like anti-aging drugs or DNA-based diets, but it has enormous implications for health and life span. And because lifestyle factors have such a profound impact, everyone has the power to take steps toward controlling and improving their BP. Its bread-and-butter primary-care medicinebut a critical part of the longevity playbook.

High blood pressure is a silent killer. There are no symptoms, yet over time the effects of high blood pressure can compound, elevating risk for heart attacks and other serious health concerns, including stroke and dementia. For this reason, managing blood pressure relatively early in life is critical, but many people arent even aware of their BP status. Though nearly half of all adults in the United States have hypertensiondefined as a blood pressure with a systolic reading at or above 130 mm Hg and a diastolic reading at or above 80 mm Hg (see below)only about one in four among this group have their condition under control.

While standard medical wisdom once advised treating to a target of <140/<90, the landmark SPRINT study found that bringing BP down to <120/<80 resulted in huge reductions in the risk of heart attack, stroke, and death from all causes. So when it comes to keeping BP in check, an aggressive approach provides the most benefitsbut where do we begin?

Blood Pressure Categories

NORMAL: < 120 mm Hg (Systolic); < 80 mm Hg (Diastolic)

ELEVATED: 120129 mm Hg (Systolic); < 80 mm Hg (Diastolic)

STAGE 1 HYPERTENSION: 130139 mm Hg (Systolic); 140 mm Hg (Diastolic)

STAGE 2 HYPERTENSION: 8089 mm Hg (Systolic); 90 mm Hg

To manage your BP, you first need to know where youre starting. While a one-time measurement might provide a rough estimate, blood pressure is subject to acute fluctuations based on hydration, stress level, posture, caffeine intake, sleep deprivation, and other variables, so a more accurate picture requires multiple measurements over a span of days. I advise patients to use a home device to check BP twice a day, at the same time each morning and evening, for at least two weeks. The average of those readings will provide a much more accurate reference value than any one-time check. From there, you can monitor changes with weekly or even monthly checks, each time taking one measurement in the morning and one in the evening. The goal in checking frequently is to recognize increases as quickly as possible to facilitate faster intervention.

The gold standard for measuring BP is with a cuff and stethoscope, but this manual method can be intimidating to learn. In my experience, automated cuffs can overestimate BP because they work on an algorithm that estimates systolic and diastolic blood pressure from a measured mean arterial pressure (average BP, essentially), but they are generally good alternatives. Ive used both the Withings (withings.com; BPM Connect, $130) and Omron (amazon.com; M3 model, $80) brand cuffs.

Because so many variables affect BP, its important to follow the same protocol for every measurement:

Sit with your back supported for five minutes before measuring. (This can feel like a long time, since you should not be looking at your phone or speaking.)

Do not cross your legs.

Check that the cuff is against your skin and fits well.

Avoid talking during the check.

Note: Having a full bladder can bump up your BP by 10 to 15 mm Hg.

This story appears in the November 2023 issue of Men's Health.

Author

Peter Attia, MD, is the author of the New York Times Bestseller, Outlive: The Science and Art of Longevity and is host of the popular health and medicine podcast, The Drive. He received his medical degree from the Stanford University School of Medicine and trained at the Johns Hopkins Hospital in general surgery. Hes the founder of Early Medical, a medical practice that helps patients lengthen their lifespan and simultaneously improve their healthspan.

See original here:
How to Accurately Measure Blood Pressure, According to Dr. Peter ... - Men's Health

A successful medical exchange event between China and Thailand has strengthened bilateral cooperation in the healthcare sector, with a focus on cutting-edge topics like regenerative medicine and anti-aging.

PUBLISHED : 23 Nov 2023 at 10:35

The China-Thailand Medical Exchange Meeting, jointly organised by Bloomage BioTechnology, Thailand's BCH Group, Lavida Medical Consultant Company, World Medical Hospital, and Thailand's Fanslink Company, was successfully conducted at World Medical Hospital in Thailand. This event signifies not only a significant occurrence in the medical sector but also a crucial milestone in medical cooperation and exchange between China and Thailand.

On the morning of November 22, 2023, over 70 deans and doctors from major Chinese cities received a warm welcome at World Medical Hospital in Bangkok, complete with traditional Thai ceremonies. They explored various departments of the hospital, with particular attention to anti-aging and reproduction units, and participated in a Sino-Thai medical exchange meeting at the same venue. The highlight of the event was a comprehensive showcase of Thailand's international medical expertise, highlighting the nation's leadership in these fields.

The primary focus of the exchange meeting was to enhance cooperation and exchange in the medical field between China and Thailand. At the beginning of the conference, Mr. Wissanu Krea-ngam, former Deputy Prime Minister of Thailand, delivered a video message emphasising the importance of medical cooperation between China and Thailand, sharing his experiences of multiple visits to China for cooperation. Furthermore, senior leaders from BCH Group, Lavida Medical, and World Medical Hospital also delivered speeches, further underlining the profound significance of medical exchanges between China and Thailand.

A special mention must be made of the outstanding speeches delivered by representatives of Lavida Medical, including Dr. Porntip, Dr. LIM WEI KHOON, and Ms. Jiang Bowen. They not only introduced the latest developments in Thai medical care to the Chinese delegation but also engaged in in-depth discussions on cutting-edge topics such as regenerative medicine and anti-aging. The Q&A session that followed was the climax of the meeting, during which both sides engaged in extensive discussions on cutting-edge anti-aging therapies and medications, medical instruments, international medical standards, and certifications, among other topics. The meeting atmosphere was warm, and the exchanges were fruitful.

The success of this exchange meeting has not only deepened the understanding and friendship between China and Thailand in the medical field but has also laid a solid foundation for future cooperation and development. After the meeting, Bloomage BioTechnology, Thailand BCH Group, and Lavida Medical exchanged gifts and took group photos, symbolising the promising future and strong friendship of China-Thailand medical cooperation. With the continued organisation of such exchange activities, we have reason to believe that cooperation between China and Thailand in the healthcare sector will flourish and benefit the people of both countries.

Read the original here:
China-Thailand Medical Exchange Strengthens Bilateral Cooperation - Bangkok Post

Vancouver, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The global medical aesthetics market size was USD 15.3 Billion in 2022 and is expected to register rapid revenue CAGR of 11.0% during the forecast period. Key factors propelling this growth include the increasing awareness of aesthetic procedures, a surge in the adoption of minimally invasive devices, a rising demand for home-based aesthetic procedures, and continuous technological advancements in aesthetic devices.

Minimally invasive and non-surgical aesthetic treatments are gaining popularity, offering practical and risk-free alternatives to traditional surgery. Procedures such as Botox, dermal fillers, laser therapy, chemical peels, and microdermabrasion are on the rise due to their minimal downtime, making them optimal for quick recovery and the resumption of routine activities. The total number of non-surgical cosmetic operations increased by 44% in 2021 compared to surgical cosmetic procedures, with a substantial growth of 63% in the body procedures category. This trend is driven by accessibility, adaptability, and reduced scarring concerns associated with non-surgical treatments.

The rising demand for home-based cosmetic procedures is a significant driver, fueled by the increasing prevalence of dermatological diseases like acne, psoriasis, and skin cancer. However, poor reimbursement conditions pose a restraint to market growth, as cosmetic procedures, equipment, and devices are often not covered by insurance providers. Recent trends include the growth of medical aesthetics tourism, the destigmatization of aesthetic procedures, and the use of the internet to find the best providers.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/2500

The facial aesthetic product segment led the market in 2022, driven by the increasing number of individuals seeking a youthful appearance and disposable financial resources. Notably, Allergan Aesthetics introduced the SkinMedica Even & Correct Collection, focusing on lightening treatments and dark-spot reduction creams. The cosmetic implant segment is expected to experience moderate growth due to clear regulatory requirements, the acceptance of bio-implants, and an increase in target diseases. Noteworthy approvals include Allergan's NATRELLE INSPIRA Soft Touch breast implants and Sientra Inc.'s gel breast implants.

The non-surgical procedures segment is anticipated to hold a significant revenue share, driven by the increasing popularity of lipolysis. Technological advancements, product introductions like Lumenis Ltd.'s NuEra Tight, and growing awareness among the elderly contribute to this segment's growth. Hospitals and clinics are expected to register fast revenue growth, driven by automated systems, early disease diagnosis, and the digitization of patient workflows. Beauty centers and medical spas, offering non-invasive skin rejuvenation procedures, are projected to account for the largest revenue share.

North America dominated the market in 2022, driven by experienced cosmetic surgeons, increased adoption of cosmetic operations, and advanced healthcare infrastructure. The Cleveland Clinic Organization estimates over 15 million cosmetic surgery treatments annually in the U.S.

The Asia Pacific region is poised for the fastest revenue growth, attributed to rising awareness of anti-aging surgeries, medical tourism, improved healthcare infrastructure, and affordable treatment costs. Government policies promoting cosmetic medicine standardization contribute to market growth.

Europe is expected to account for a substantial revenue share, driven by the demand for high-quality aesthetic procedures, established healthcare infrastructure, and an effective reimbursement system. The rising number of aesthetic operations is also a contributing factor. The global medical aesthetics market is experiencing significant growth driven by a shift towards minimally invasive treatments, increasing demand for home-based procedures, and ongoing technological advancements. Market players are responding with innovative products, contributing to the expansion of the industry.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/2500

Medical Aesthetics Report Summary

Medical Aesthetics Top Companies and Competitive Landscape

The global medical aesthetic market is fairly fragmented with many large and medium-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective medical aesthetic solutions. Some major players included in the global medical aesthetic market report are:

Medical Aesthetics Latest Industry News

Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/2500

Medical Aesthetics Market Segment Analysis

For the purpose of this report, Emergen Research has segmented global medical aesthetic market on the basis of product, procedure, end-use, and region:

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/medical-aesthetics-market

Curated Reports You Shouldn't Miss: Dive In Now!

Patient Registry Software Market By Delivery, By Database, By Registry Type, By Function, By Software Type (Integrated, Standalone), By End-use (Government & Third-Party Administrators, Pharmaceutical Companies, Hospitals, Research Centers, Others), and By Region, Forecast to 2027

Operating Room Management Solutions Market, By Component (Software and Services), By Solution, By Delivery Mode (On-Premises and Cloud-based), By End-Use, and By Region Forecast to 2030

Medical Smart Textiles Market By Technology (Textile Sensors, Wearable Technology), By Application (Surgery, Bio-Monitoring, Therapy, and Wellness), By End-use (Hospitals and Clinics, Medical Academic and Research Center), and By Region Forecast to 2027

Topical Drug Delivery Market By Product Form (Semi-Solid, Solid Formulations, Transdermal Products, and Liquid Formulations), By Route (Dermal, Ophthalmic, Nasal, Others), By End-Use (Hospitals, Home Healthcare, Clinics, Diagnostic Centers, Burn Center), and By Region Forecast to 2027

Advanced Prosthetics and Exoskeletons Market By Product Type (Lower Limb, Upper Limb, Full Body), By Application (Hospitals, Clinics, Orthotic and Prosthetic Centers, Others), By Mobility (Stationary, Mobile), and By Region, Forecast to 2028

Robotics Surgical Simulation Systems Market By Product & Service Type (Conventional Surgery Simulation, Minimally Invasive Surgery Simulation, Others), By Type of Surgery (General Surgery, Endoscopic Surgery, Neurological Surgery, Gynecological Surgery, Cardiac Surgery), By End-use (Hospitals, Surgical Centers, Ambulatory Surgical Centers, Others), and By Region, Forecast to 2028

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights

See the rest here:
Medical Aesthetics Market Size Worth USD 43.2 Billion in 2032 ... - GlobeNewswire

Animals

A total number of 34 male and female CD-1 mice with a body weight of 3545g and an age of 1820 months were used. The age of 1820 months was chosen according to reports of others, demonstrating age-associated physiological alterations and tumor development after 1618 months in male and 18 months in female CD-1 mice [16]. The animals were bred at the Institute for Clinical and Experimental Surgery, Saarland University, Germany, and housed at a regular light and dark cycle with free access to tap water and standard pellet food (Altromin, Lage, Germany).

All experiments were performed according to the German legislation on the protection of animals and the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Research Council, Washington DC, USA). The experiments were approved by the local governmental animal protection committee (permit number: 04/2019).

Mice were anesthetized by intraperitoneal (i.p.) injection of ketamine (75mg/kg body weight, Ursotamin, Serumwerke Bernburg, Bernburg, Germany) and xylazine (15mg/kg body weight, Rompun, Bayer, Leverkusen, Germany). The pin-clip model using a segmental defect served as control and was performed as described previously [15]. Under aseptic conditions, a ~4mm medial parapatellar incision was created at the right knee and the patella was dislocated laterally. After drilling a hole (diameter of 0.50mm) into the intracondylar notch, a distally flattened pressfit 24 Gauge needle (diameter of 0.55mm) was implanted intramedullary and the wound was closed. The pin was flattened at the distal end to avoid secondary dislocation. After insertion of the pin, the diaphysis of the femur was exposed by a lateral approach. Subsequently, a custom-made clip of 6mm length was implanted ventrodorsally into the femur and lateral of the already implanted pin. A gap size of 1.8mm was created by means of a spherical trephine under permanent saline solution cooling. Moreover, the periosteum was stripped 2mm proximally and distally of the gap along the longitudinal axis of the femoral bone. The implant position was confirmed by radiography (MX-20, Faxitron X-ray Corporation, Wheelin, IL, USA). All procedures were done under an operating microscope, guaranteeing a high level of precision. For analgesia the mice received tramadol-hydrochloride (Grnenthal, Aachen, Germany) in the drinking water (1mg/mL) 1 day prior to surgery until 3 days after surgery.

Seventeen mice were daily treated with 200mg/kg body weight PTH 134 (Bachem AG, Budendorf, Switzerland) dissolved in 100 L saline, subcutaneously (PTH group). Control animals (n=17) received an equal amount of saline (control group), subcutaneously. The used PTH dosage corresponds to other experimental studies investigating the effects of PTH on fracture healing in mice [13]. At 2 weeks [n=5 each group (3 male; 2 female)] and 10 weeks [n=9 each group (5 male; 4 female)] the animals were euthanized by an overdose of anesthetics and the femora were excised for further CT and histological analyses. Additional animals were euthanized accordingly at 2 weeks [n=3 each group (2 male; 1 female)] and tissue was harvested for Western blot analyses.

At 2 and 10 weeks after surgery the animals were anesthetized and lateral radiographs of the osteotomized femora were performed. Bone healing was analyzed according to the Goldberg score with stage 0 indicating radiological non-union, stage 1 indicating possible union and stage 2 indicating radiological union [17].

The specimens were scanned (Skyscan 1176, Bruker, Billerica, MA) at a spatial resolution of 9m with a standardized setup (tube voltage: 50kV; current: 200 A; intervals: 0.4; exposure time: 3500 ms; filter: 0.5mm aluminum). Images were stored in three-dimensional arrays. To express gray values as mineral content (bone mineral density; BMD), calcium hydroxyapatite (CaHA) phantom rods with known BMD values (0.250 and 0.750g CaHA/cm3) were employed for calibration. The region of interest (ROI) defining the novel bone was contoured manually excluding any original cortical bone. The thresholding allowed the differentiation between poorly and highly mineralized bone. The threshold to distinguish between poorly and highly mineralized bone was based upon visual inspection of the images, qualitative comparison with histological sections and other studies investigating bone repair and callus tissue by CT [18, 19]. A BMD with more than 0.642g/cm3, resulting in gray values of 98255, was defined as highly mineralized bone. Poorly mineralized bone was assumed to have a BMD value between 0.410g/cm3 and 0.642g/cm3, resulting in gray values of 6897.

The following parameters were calculated from the callus region of interest for each specimen: poorly mineralized bone volume (PM), highly mineralized bone volume (HM), bone volume fraction of tissue volume (BV/TV), bone surface (BS) density (BS/TV), trabecular thickness, trabecular separation and trabecular number.

After removal of the soft tissue and the implants, the bending stiffness of the isolated femora was measured by a 3-point-bending device using a non-destructive approach. This allowed the subsequent use of the specimens for CT as well as histological and immunohistochemical analyses and, thus, a reduction of the number of laboratory animals. Due to the different stages of healing, the loads, which had to be applied, markedly varied between individual animals. Loading was stopped individually in every case when the actual load-displacement curve deviated more than 1% from linearity. Bending stiffness (N/mm) was calculated from the linear elastic part of the load-displacement diagram [20].

After biomechanical testing and CT analysis, bones were fixed in paraformaldehyde for 24h. Subsequently, the specimens were embedded in a 30% sucrose solution for another 24h and then frozen at 80 C. Longitudinal sections through the femoral axis with a thickness of 4m were cut by the Kawamotos film method [21, 22] for histomorphometric analyses and stained with Safranin-O. At a magnification of 12.5 (Olympus BX60 Microscope, Olympus, Shinjuku, Japan; Zeiss Axio Cam and Axio Vision 3.1, Zeiss) structural indices were calculated according to the recommendations of Gerstenfeld et al. [23]. The following histomorphometric parameters of the bone defects were evaluated: (i) total callus area, (ii) bone callus area, (iii) cartilaginous callus area and (iv) fibrous callus area. The total callus area was defined as the entire osseous, cartilaginous and fibrous callus tissue between the two drilling holes of the clip outside of the cortices. Pre-existing cortical bone of the proximal and distal fragment, however, was excluded. Each area was marked and calculated using the ImageJ analysis system (NIH, Bethesda, USA).

In addition, tartrate-resistant acid phosphate (TRAP) activity was analyzed in the callus tissue at 2 and 10 weeks after surgery. For this purpose, longitudinal sections of 4m were incubated in a mixture of 5mg naphotol AS-MX phosphate and 11mg fast red TR salt in 10 mL 0.2M sodium acetate buffer (pH 5.0) for 1h at 37C. Sections were counterstained with methyl green and covered with glycerin gelatin. TRAP-positive multinucleated cells (three or more nuclei each cell) were counted. In the specimens, one high-power field (HPF, 400 magnification) was placed in a standardized manner in the central region of the callus, while three additional HPFs were placed on each site of the periosteal callus.

To analyze the cellular composition within the callus tissue of atrophic non-unions at 2 and 10 weeks after surgery, longitudinal sections with a thickness of 4m were cut. For the immunohistochemical detection of microvessels, sections were stained with a monoclonal rat anti-mouse antibody against the endothelial cell marker CD31 (1:100; Abcam, Cambridge, UK). A goat anti-rat IgG-Alexa555 antibody served as secondary antibody (1:100; Life Technology, Eugene, USA). Cell nuclei were stained with Hoechst 33342 (2g/mL; Sigma-Aldrich, Taufkirchen Germany). To detect the neutrophilic granulocyte marker myeloperoxidase (MPO) and the macrophage marker CD68, sections were stained with a polyclonal rabbit anti-mouse antibody against MPO (1:100; Abcam) and a polyclonal rabbit anti-mouse antibody against CD68 (1:100; Abcam). A goat anti-rabbit IgG-antibody (1:200; Dianova, Hamburg, Germany) served as corresponding secondary antibody.

In the specimens, the number of CD31-positive microvessels as well as MPO- and CD68-positive cells was counted. For this purpose, one HPF was placed in a standardized manner in the central region of the callus, while three additional HPFs were placed on each site of the periosteal callus.

Protein expression within the callus tissue was determined by Western blot analysis, including the expression of vascular endothelial growth factor (VEGF), cyclooxygenase (COX)-2 and phosphoinositide 3-kinase (PI3K). The callus tissue was frozen and stored at 80C until required. Analyses were performed from callus tissue at 2 weeks after surgery (n=3 each group). After saving the whole protein fraction, analysis was performed using the following antibodies: rabbit anti-mouse VEGF (1:300, Abcam, Cambridge, UK), COX-2 (1:30, Abcam) and mouse anti-mouse PI3K (1:100, Santa Cruz Biotechnology, Heidelberg, Germany). Primary antibodies were followed by corresponding horseradish peroxidase-conjugated secondary antibodies (1:1000, R&D Systems). Protein expression was visualized by means of luminol-enhanced chemiluminescence after exposure of the membrane to the Intas ECL Chemocam Imager (Intas Science Imaging Instrument GmbH, Gttingen, Germany) and normalized to -actin signals (1:1000, mouse anti-mouse -actin, Santa Cruz Biotechnology) to correct for unequal loading.

All data are given as meansSEM. After testing the data for normal distribution (KolmogorovSmirnov test) and equal variance (F-test), comparisons between the two groups were performed by an unpaired Students ttest. For nonparametrical data, a MannWhitney Utest was used. All statistics were performed using the SigmaPlot 13.0 software (Jandel Corporation, San Rafael, CA, USA). A pvalue of <0.05 was considered to indicate significant differences.

Read the original:
Parathyroid hormone stimulates bone regeneration in an atrophic ... - Journal of Translational Medicine

Chanel's research uncovered the benefits of red camellia extract from the Camellia Japonica 'Czar' species. The odorless flower has an enduring quality, as evidenced by petals that are unaffected by water or cold. They are hand-picked at full turgescency and contain protocatechuic acid, a powerful and nutritive molecule not found in the previous camellias studied. This species, in particular, has a remarkable ability to support skin vitality, which has been translated into the No.1 De Chanel range, which addresses the first stage of skin aging. Its antioxidant content rejuvenates and keeps skin looking young.

The formulas in the collection contain up to 97% natural and renewable ingredients, with camellia derivatives accounting for 75% of the total. To reduce waste, various plant parts are used in the formula and packaging. The extract is used for its rejuvenating properties, while the camellia water soothes. The oil obtained by pressing the seeds keeps the complexion moist, while the seed shells are used in the packaging of the 'Revitalizing Cream'.

The range comprises nine products, including the new Powder-To-Foam cleanser that becomes creamy upon contact with water. Other skincare products include a pore-tightening lotion, a revitalizing serum, a smoothening cream, and an accompanying eye cream to target dark circles and puffiness. As for makeup, red camellia oil is infused into the hydrating foundation, and lip and cheek balm. The Lau Rouge Revitalizing Fragrance Mist keeps skin fresh all day while also functioning as a fragrance. The camellia is odorless, but its scent is reimagined as a floral bouquet of jasmine, orange blossom, and rose. An exquisite skincare and makeup line with the benefits of the camellia flower! PS: the camellia is also Chanel's fashion emblem.

The luxurious Guerlain Orchide Impriale Cream, a cult beauty elixir for over 15 years, is synonymous with the most advanced orchid skincare research.s. Endowed with extraordinary longevity, these blooms provide potent cosmetic anti-aging properties. Guerlain's Orchidarium's most recent research has discovered the secret of infinite longevity, which was discovered in the deepest roots of an extraordinary duo of orchids chosen from over 30,000 species.

The first is Gastrodia Elata, a legendary herb used in Traditional Chinese Medicine that grows in the mountains of Yunnan and other parts of China. Aside from its exceptional regenerating properties, a precious fraction extracted from its roots has been found to immediately combat a lack of cell oxygen and to protect skin cells. The second is the Dendrobium Fimbriatum, which lives on the surface of tree trunks or branches and has a remarkable ability to survive. Its extraordinary aerial roots, in particular, synthesize a wide range of molecules.

The regenerative power of both orchid roots has now been concentrated in the cutting-edge Orchid Totum technology. This molecular extract, which is made up of many different molecules, helps to regulate cell respiration, fight hypoxia, and, for the first time, targets a longevity enzyme, PHD3, which can dramatically reverse the visible signs of aging. Guerlain collaborated with the prestigious Swiss Federal Institute of Technology in Zurich to discover the enzyme.

Aside from the Orchid Totum, the Guerlain Orchide Impriale Cream 2022 has an exceptional sensory feel infused into a formula made up of 96% naturally derived ingredients. The cream is ultra-fine, soft and emollient, rich and plumping, and provides all-day hydration. After seven days of use, study subjects aged 18 to 72 had skin that appeared three years younger, based on a comparison of dermis density using approximately 6,000 skin ultrasounds. Dermatologists' clinical evaluations also revealed a significant improvement in the visible signs of aging, ranging from increased radiance to wrinkle reduction to increased hydration.

Cl de Peau Beaut's Synactif collection, inspired by detoxifying spa treatments and backed by cutting-edge science, was launched in 2004 and sits at the pinnacle of the luxury Japanese beauty brand's offerings. It targets the skin's natural impurity removal processes and supports the skin's self-beautifying system for youthful, radiant, sculpted beauty.

Synactif is a complete and holistic regimen that provides a combination of efficacy and experience, the latter of which is enhanced in part by a key ingredient: the Synactif Rose. It was first commissioned by France's renowned Delbard nursery in search of a fragrance that would embody the relaxing, harmonious, and purifying qualities of the Synactif line.

So perfect was the result that the rose won the Best Fragrance Award at the Bagatelle International Rose Competition. The fragrance is inspired by the moment the flower blooms, releasing its precious scent for a mere few hours in the mornings of May. It was then incorporated into each step of the Synactif regimen to offer the ultimate sensorial experience.

The longoza flower, grown in the Maison's garden in the heart of the Indian Ocean, is the secret behind Dior's Capture Totale collection. Madagascar is home to a biodiverse ecosystem with 13,500 endemic flowers, 75 percent of which are not found anywhere else.

A Dior garden in the Ranomafana area of the rainforest combines traditional hand-harvesting with a rigorous extraction method. The house has been researching the legendary longoza for 30 years. The scarlet flower, which means 'eternal' in Madagascan, never dies and regenerates when cut, earning it the nickname 'Phoenix flower'.The longoza can resurrect itself in the harshest of environments. As a skincare extract, it has a powerful regenerative quality in the face of cellular fatigue - a condition in which cells struggle to renew and absorb nutrients, leaving the complexion vulnerable to visible signs of aging. The extract helps the skin's mother cells by resetting them with powerful nutrients to restore the complexion's radiance.

This year, after five years of research, Dior unveils its breakthrough development of the Longoza-Ferments Blend a first in the Capture Totale range. The biotechnology solution is created through a 10-step flash multi-fermentation process, during which the flower is put into contact with 10 ferments for 10 days. In its natural state, longoza seeds contain 50 active molecules. This innovation maximizes their active molecular content, triggering optimal efficacy and ability to be absorbed by the skin.

The newly launched Capture Totale Intensive Essence Lotion contains a 75 percent infusion of this potent blend. This high concentration helps the skin cells to achieve the houses pillars of skin quality including clearness, moisture, and strength. With daily application in the morning, the skin is reset for the day. Plumpness and radiance are restored, while signs of fatigue and stress are visibly reduced.

The rose may be the worlds most well-known and adored flower. A symbolic flower in so many moments of life, its also a primary part of Lancmes heritage as a beauty brand. The first rose was created for Lancme in 1973 and is known for its exceptional color and long-lasting blooms. It was the first rose used in biotechnology for skincare. Now, 37 years later we feature a new variation of the precious flower at Lancme with the Absolue Perpetual Rose.

Lancme's International Scientific Director, Dr. Annie Black, explained what the composition is of the Absolue Perpetual Rose extract and why is it unique compared to other roses. According to Dr. Black, the unique terroir of the Plateau de Valensole contributes to the one-of-a-kind potential of this rose. Part of the Verdon Natural Park, near the Gorges du Verdon and its lakes in the Alpes-de-Haute-Provence, the privileged location benefits from a climate that is half-Mediterranean and half-Alpine and allows for exceptional quality roses to be grown on the Plateau. The beautiful rose fields of the Plateau de Valensole are carefully overseen by third-generation farmer, Madame Emmanuelle Ravel, who ensures each rose receives the love and care it deserves. The exquisite rose fields contain over 5,000 different rose bushes which bloom on three acres of land and are grown according to organic farming principles.

The Absolue Perpetual Rose is organically grown and special care and consideration are in place for the extraction process. Hand harvested in the early morning when the flowers start to bloom, the roses are swiftly brought to the nearby factory for extraction. The secret is to waste as little time as possible between the harvest in the fields and the extraction process. It is extracted for its use in skincare uniquely and sustainably, captured through a unique green technology process that enables upcycling of ingredients that were previously discarded for use in the company's skincare formulas. In this process, CO2 is leveraged to extract the exclusive rose molecules while producing minimal rose bio-waste.

Grand Rose Extracts is Lancmes Proprietary Blend of rose extracts sourced exclusively from the South of France and is infused in their Absolute Skin Surface Cell Renewing Serum. In this formulation, the Absolue Perpetual Rose is paired with Rose Centifolia extract, also known as Rosewood, an ingredient that was usually discarded during extraction, but is now upcycled and used for the first time as an antioxidant.

It's amazing to see how flowers are being used more and more for different purposes. If you're keen to hype up your skincare routine, these might be the next products you're looking for.

Go here to read the rest:
These Luxury Brands Use Flowers in Their Skincare Products ... - Thursd